Quadrant Capital Group LLC Cyma Bay Therapeutics, Inc. Transaction History

Quadrant Capital Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $1,531 - $2,484	141 Added 59.75%	377 $5,000
Q2 2022 Aug 09, 2022	SELL	$1.72 - $3.39 $342 - $674	-199 Reduced 45.75%	236 $1,000
Q1 2022 May 06, 2022	BUY	$2.77 - $3.64 $1,204 - $1,583	435 New	435 $1,000
Q3 2021 Nov 12, 2021	SELL	$3.47 - $4.42 $371 - $472	-107 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$3.94 - $4.92 $421 - $526	107 New	107 $0

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.